{"id":12770,"date":"2011-09-01T08:59:30","date_gmt":"2011-09-01T12:59:30","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=12770"},"modified":"2011-09-01T09:19:01","modified_gmt":"2011-09-01T13:19:01","slug":"the-sounds-of-hammers","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/09\/01\/the-sounds-of-hammers\/","title":{"rendered":"the sounds of hammers&#8230;"},"content":{"rendered":"<br \/>\n<blockquote>\n<div align=\"center\"><u><strong><a target=\"_blank\" href=\"http:\/\/quotes.wsj.com\/AZN\/interactive-chart\"><font color=\"#200020\">AstraZeneca Still Falling Behind Rivals<\/font><\/a><\/strong><\/u><br \/>               <strong><font color=\"#200020\">Wall Street Journal<\/font><\/strong><br \/>              By Hester Plumridge<br \/>              7\/29\/2011<\/div>\n<p>             <\/p>\n<div align=\"justify\"><sup>If drugs companies are scaling a cliff, AstraZeneca [AZN] looks stuck at the bottom. Sales at the U.K. pharmaceutical company fell 2% in the second quarter, while those at rivals Sanofi and Novartis  rose 7% and 19%, respectively. AstraZeneca&#8217;s shares are the  lowest-rated of all large-cap pharmaceuticals, and it&#8217;s hard to see them  making up that ground. As a swath of blockbuster drugs developed  in the 1980s and 1990s now face generic competition, some companies are  faring better than others at making up lost sales&#8230;<\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\">There are some people who read the <strong><font color=\"#200020\">Wall Street Journal<\/font><\/strong>, watch <strong><font color=\"#200020\">CNBC<\/font><\/strong>, and check on the market throughout the day. There are others who looked at it the day after it plummeted in 2008 to see what the fuss was about on last night&#8217;s news. I&#8217;m in group B. It&#8217;s like the weather channel &#8211; something to watch when a hurricane is coming, but otherwise an intervening number on the way to something else. But the Internet is saturated with articles like the one above, generated in an endless flow that I&#8217;m sure would circumnavigate the earth if placed end to end many times in a given day. This morning, I checked in on AZN after Dr. Stahl mentioned <strong><font color=\"#660033\">AstraZeneca<\/font><\/strong> closing various labs. I <a target=\"_blank\" href=\"http:\/\/www.google.com\/search?q=astrazeneca\"><u><strong><em><font color=\"#660033\">Googled<\/font><\/em><\/strong><\/u><\/a> them and clicked <strong><em><font color=\"#660033\">News<\/font><\/em><\/strong>. 0.11 seconds later <strong><font color=\"#660033\">Google<\/font><\/strong> provided 1,250 sites to choose from. I didn&#8217;t get them all finished, but in a quick run-through, I didn&#8217;t find any mention of the <em>Pharma-scold<\/em>s, or Carlat&#8217;s blog, or Scientology. I did find out about some ups and downs:<\/div>\n<blockquote>\n<div align=\"justify\"><sup>This month, its best pipeline hope, blood-thinner  Brilinta, gained U.S. approval, adding a potential $1.5 billion to $3.5  billion onto 2014 sales. But overall, AstraZeneca&#8217;s recent track record  is poor. A panel that advises on U.S. drug approvals voted this month  not to recommend its new diabetes drug. Lung disease and high  cholesterol treatments were discontinued last year.<\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\">I read about some cost-cutting maneuvers:<\/div>\n<blockquote>\n<div align=\"justify\"><sup>AstraZeneca already has sold noncore assets, agreeing to sell its  dental and surgical product business, AstraTech, for $1.8 billion in  June. In the coming year there looks little by way of drug-development  news that could materially boost earnings expectations&#8230;<\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\">I&#8217;d be guessing that rather that the complex psychodrama described in Dr. Stahl&#8217;s now famous rant, the closing of AZN&#8217;s CNS Division&#8217;s R&amp;D labs was no more deeply motivated than as a cell on a spread-sheet under the column <strong><font color=\"#200020\">Non-core Assets<\/font><\/strong> [somewhere below Dentistry]. This is what runs such enterprises, &quot;<em><strong><font color=\"#200020\">In the coming year there looks little by way of drug-development  news that could materially boost earnings expectations<\/font><\/strong>,<\/em>&quot; not something so lofty as, <strong><font color=\"#200020\">&quot;<em>Pharma  have heard these protests loud and clear and are now pulling out of  psychiatric research<\/em>&quot;<\/font><\/strong> [<a href=\"http:\/\/go.neiglobal.com\/Blog\/tabid\/83\/EntryId\/16\/Are-future-psychiatric-treatments-doomed-Be-careful-what-you-ask-for-you-just-might-get-it.aspx\" target=\"_blank\"><u><strong><font color=\"#330066\">Stahl 2011<\/font><\/strong><\/u><\/a>]. On Carlat&#8217;s blog, Dr. Debbi Ann Morrissette, Dr. Stahl&#8217;s spokesperson <a target=\"_blank\" href=\"http:\/\/carlatpsychiatry.blogspot.com\/2011\/08\/dr-stahls-medical-writer-fights-back.html?showComment=1314833698791#c1025322198662980366\"><u><strong><font color=\"#200020\">comments<\/font><\/strong><\/u><\/a>:<\/div>\n<blockquote>\n<div align=\"justify\"><sup>&quot;As our understanding of the brain and the influence of genetic and  environmental factors increases we&#8217;ll have a better &#8216;big picture&#8217; view  of what goes wrong in the individual patient and how to fix it. In  searching for that &quot;big picture&quot; there will inevitably be failures and  successes. The bottom line is: we need to keep trying and like it or  not, Pharma is our ally in this effort.&quot;<\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\">There are several Mythologies in the formulations of Drs. Stahl and Morrissette that bear correcting. First, the <strong><font color=\"#200020\">Myth of the Centrality of Psychopharmacology in the mind of Pharma<\/font><\/strong>. It&#8217;s not there now, nor has it ever been. Psychopharmacology just happened to provide the soil for the planting of some blockbusters [drugs exceeding $1 B sales]. Now it&#8217;s time to rotate the crops. CNS Medicine was a seasonal crop. Then there&#8217;s the <strong><font color=\"#200020\">Myth of the Alliance between Psychiatry and Pharma<\/font><\/strong>. Dr. Morrissette says, &quot;<strong><font color=\"#200020\"><em>The bottom line is: we need to keep trying and like it or  not, Pharma is our ally in this effort.<\/em><\/font><\/strong>&quot; Pharma is not now nor has it ever been our ally. She&#8217;s been reading way too many ads. Pharma is a business venture operating on this formula:<\/div>\n<div align=\"center\"><sup><strong><font color=\"#200020\">Profits = Sales &#8211; Development &#8211; Production &#8211; Marketing &#8211; Settlements &#8211; Legal Fees<\/font><\/strong><\/sup><\/div>\n<div align=\"justify\">There&#8217;s no alliance that transcends that formula. She&#8217;s misunderstood the way we critics have used the term &#8211; &quot;alliance.&quot; What we&#8217;ve said is &quot;unholy alliance.&quot; Now that Psychopharmacology has become a <strong><font color=\"#200020\">Non-core Asset<\/font><\/strong>, this mythical alliance with Pharma is dissolving as quickly as it appeared twenty-five years ago. <\/div>\n<p align=\"justify\">My guess is that our problems with things like Conflicts of Interest, Pharma contaminated CME programs, the corruption of our literature, the Speakers Bureaus, etc. will lighten considerably in the coming years, even if we do dawdle in officially plugging the holes. I&#8217;m, of course, hardly advocating dawdling &#8211; there&#8217;s much to be done to restore scientific integrity and the medical ethic to it&#8217;s proper place. But the tea leaves say that Pharma&#8217;s empty CNS pipeline isn&#8217;t going to be funding those endeavors much longer.    <\/p>\n<hr width=\"75%\" size=\"1\" \/>     <\/p>\n<div align=\"justify\"><sup><em>I live in a beautiful and somewhat undeveloped area north of Atlanta that was crawling with developers hoping to score big time when I retired and we moved up here. A few years later, the &quot;housing bubble&quot; burst. As house prices began to fall, the developers, the mortgage brokers, and the real estate speculators were slow to hear the music &#8211; redoubling their efforts to keep their dreams alive. They lost their shirts trying to defeat what was, in retrospect, as inevitable as the earth&#8217;s journey around the sun. I still live in a beautiful and somewhat undeveloped area north of Atlanta. We haven&#8217;t heard the sounds of hammers or processed any new building permits around here for some time. Other than the clearing of some land along the highway for the obligatory Wallmart, the main source of deforestation has been the odd tornado. I wonder why I thought of that story?<\/em><\/sup><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca Still Falling Behind Rivals Wall Street Journal By Hester Plumridge 7\/29\/2011 If drugs companies are scaling a cliff, AstraZeneca [AZN] looks stuck at the bottom. Sales at the U.K. pharmaceutical company fell 2% in the second quarter, while those at rivals Sanofi and Novartis rose 7% and 19%, respectively. AstraZeneca&#8217;s shares are the lowest-rated [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-12770","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/12770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=12770"}],"version-history":[{"count":28,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/12770\/revisions"}],"predecessor-version":[{"id":12798,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/12770\/revisions\/12798"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=12770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=12770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=12770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}